Andrew Crockett, KalVista CEO

KalVista ends a PhII study ear­ly af­ter pa­tients suf­fer se­vere and life-threat­en­ing side ef­fects

KalVista took a beat­ing Tues­day af­ter an­nounc­ing it would scrap a Phase II tri­al for one of its ex­per­i­men­tal drugs.

The biotech said in an ear­ly morn­ing press re­lease that it is ter­mi­nat­ing the study for KVD824 af­ter mul­ti­ple pa­tients in every treat­ment group saw un­safe, el­e­vat­ed lev­els of cer­tain liv­er en­zymes. By end­ing the tri­al now, KalVista hopes to save some mon­ey and fun­nel it to­ward an­oth­er study for its lead pro­gram, CEO An­drew Crock­ett said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.